Donald Trump, MD, FACP

President and CEO

Professor

Roswell Park Cancer Institute

Professor of Medicine and Pharmacology

School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Profile

Areas of Expertise:

Bladder Cancer

Kidney Cancer

Prostate Cancer

Testicular Cancer

Biography:

Dr. Donald L. Trump was appointed President and Chief Executive Officer of Roswell Park Cancer Institute (RPCI) on April 1, 2007. On first coming to RPCI in January 2002, Dr. Trump served as Senior Vice President for Clinical Research; Chair, Department of Medicine; and Co-Principal Investigator (PI) of the Cancer Center Support Grant (CCSG) funded by the National Cancer Institute. He was appointed Associate Institute Director in the fall of 2006 and became President and CEO of RPCI, and PI of the CCSG, in 2007.

Dr. Trump has direct authority over day-to-day operations, philanthropic and operating budgets, capital improvements, research priorities and clinical and scientific strategic planning for the Institute. He is responsible for establishing a culture of excellence throughout RPCI’s key mission areas: research, clinical care, education and cancer prevention.

In addition to his role as President and CEO, Dr. Trump continues his work as a clinical scientist and physician. He leads the Institute’s strong clinical research program in vitamin D-based cancer prevention and treatment, and he cares for patients with prostate cancer and other urologic cancers. He is principal investigator or co-principal investigator on several grants funded by the National Cancer Institute. He holds European and U.S. patents for the use of vitamin D and vitamin D analogs in combination with high-dose chemotherapy.

Dr. Trump earned his medical degree from The Johns Hopkins University School of Medicine, Baltimore, MD, in 1970. From 1970 to 1975, he completed an internship and residency training in Medicine and a fellowship in Oncology and served as Chief Resident in Internal Medicine at The Johns Hopkins Hospital. Dr. Trump is a Diplomate of the American Board of Internal Medicine, with Subspecialty Boards in Medical Oncology, and a Fellow of the American College of Physicians.

Dr. Trump is past Secretary/Treasurer of the American Society of Clinical Oncology, and is a member of many professional and scientific societies. Together with his collaborator, Dr. Candace Johnson, Deputy Director of RPCI, Dr. Trump has co-edited a recent textbook entitled Vitamin D and Cancer (Springer). In May 2009 he was inducted into the Johns Hopkins University Society of Scholars. He is a reviewer and/or member of the editorial board of prestigious journals, such as the New England Journal of Medicine, Journal of the National Cancer Institute, Cancer, Journal of Urologic Oncology, Clinical Cancer Research, Cure, Oncology, American Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Cancer Research, and Journal of Clinical Oncology. Dr. Trump has authored or co-authored more than 200 journal publications, book chapters and abstracts.

Research

Research Interests:

Novel therapeutics in prostate and bladder cancer

High dose vitamin D as a cancer therapeutic

Vitamin D insufficiency in cancer patients

Role of vitamin D supplementation in cancer prevention and morbidity reduction

Role of vitamin D in cancer prevention and treatment

Background Information

Education and Training:

MD - Johns Hopkins University School of Medicine, Baltimore, MD

Residency:

Internal Medicine, Johns Hopkins Hospital, Baltimore, MD

Chief Resident, Osler Medical Service, Johns Hopkins Hospital, Baltimore, MD

Board Certification:

Internal Medicine, American Board of Internal Medicine

Medical Oncology, American Board of Internal Medicine

Fellowships:

Medical Oncology, Johns Hopkins Hospital, Baltimore, MD

Publications

Publications:

Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, Wong M, Johnson C, Trump DL. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer 2010; 116(9):2132-2139
Ma Y, Yu W-D, Trump DL, Johnson CS. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 2010; 116(13):3294-3303
Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer journal (Sudbury, Mass.) 2010; 16(1):1-9
Deeb KK, Liu Song, Luo Wei, Karpf AR, Morrison C, Johnson CS, Trump DL. Molecular features of endothelial cells isolated from benign and malignant prostatic tissues. Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:310
Hidalgo AA, Trump DL, Johnson CS. Glucocorticoid regulation of the vitamin D receptor. Journal of steroid biochemistry and molecular biology 2010; 121(1-2):372-375
Johnson CS, Chung I, Trump DL. Epigenetic silencing of CYP24 in the tumor microenvironment. Journal of steroid biochemistry and molecular biology 2010; 121(1-2):338-342
Krishnan AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. Endocrinology and metabolism clinics of North America 2010; 39(2):401-418, table of contents
Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, Trump DL. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer research 2010; 70(14):5953-5962
Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Trump DL, Johnson CS. Regulation of vitamin D 24-hydroxylase gene expression in human prostate cancer by epigenetic mechanisms. Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:1202
Ma Y, Trump DL, Johnson CS. Vitamin D in combination cancer treatment. Journal of Cancer 2010; 1:101-107
Ma Y, Su B, Yu W-D, Seshadri M, Turowski SG, Kong R-X, Gillard BM, Trump DL, Johnson CS. 1,25D(3) regulates cell-matrix and cell-cell adhesion and reduces experimental metastasis in a squamous cell carcinoma model system. Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:1243
Malone EK, Rassnick KM, Wakshlag JJ, Russell DS, Al-Sarraf R, Ruslander DM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours. Veterinary and comparative oncology 2010; 8(3):209-220
Mazzilli SA, Reid ME, Foster BA, Johnson CS, Trump DL. The effects of l alpha,25-dihydroxyvitamin D3 (calcitriol) on the tumor-igenesis of lung squamous cell carcinoma. Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:460
Michalek AM, Hutson AD, Wicher CP, Trump DL. The costs and underappreciated consequences of research misconduct: a case study. PLoS medicine 2010; 7(8):e1000318
Muindi JR, Yu W-D, Ma Y, Engler KL, Kong R-X, Trump DL, Johnson CS. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 2010; 151(9):4301-4312
Muindi JR, Adjei AA, Wu ZR, Tian L, Sucheston LE, Johnson CS, Trump DL, Fakih MG. A comprehensive characterization of cholecalciferol supplementation induced changes in the vitamin D-3 metabolic pathway in metastatic colorectal cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:21
Yu W-D, Ma Y, Flynn G, Muindi JR, Kong R-X, Trump DL, Johnson CS. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell cycle (Georgetown, Tex.) 2010; 9(15):3022-3029
Puthillath A, Trump DL, Andrews C, Bir A, Romano K, Wisniewski M, Fakih MG. Serological immune responses to influenza vaccine in patients with colorectal cancer. Cancer chemotherapy and pharmacology 2011; 67(1):111-115
Rassnick KM, Muindi JR, Johnson CS, Bailey DB, Trump DL. Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs. Cancer chemotherapy and pharmacology 2011; 67(1):165-171
Chadha MK, Fakih M, Muindi J, Tian L, Mashtare T, Johnson CS, Trump D. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients. Prostate 2011; 71(4):368-372
Lee HJ, Trump D, Johnson CS, Wang ES, Thompson JE, Griffiths EA, Vigil CE, Barcos M, Block A, Sait S, Ford LA, Wilding G, Wei T, Muindi J, Wetzler M. Subnormal vitamin D levels are associated with adverse outcome in newly-diagnosed similarly-treated adult acute myeloid leukemia (AML) patients. Blood 2010; 116(21):Abstract #1041
Iyer RV, Johnson CS, Ramnath N, Fakih M, Muindi J, Wilding GE, Tan W, Javle MM, Fetterly GJ, Trump DL. Enhanced gemcitabine (G) exposure in combination with escalating doses of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] (P) in patients with advanced malignancies. Journal of clinical oncology 2010; 28(15 Suppl.):e13031
Trump DL, Morris T, Taboada M, Nathan FE, Burris HA, Stephenson J, De Bono JS, Miller K, Payne H, Hubner A. Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety. Journal of clinical oncology 2010; 28(15 Suppl.):4664
Messing EM, Crawford E, Tangen C, Natale RB, Trump DL, de Vere White R, Grossman HB, Scosyrev E, Ely B, Thompson I. Do mixed histologic features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? : 2010 Genitourinary Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract #274
Trump DL, Morris T, Taboada M, Nathan FE, Burris III HA, Stephenson J, De Bono JS, Miller K, Payne H, Hübner A. Safety and efficacy of the specific endothelin A receptor antagonist zibotentan (ZD4054) plus docetaxel in patients with metastatic hormone-resistant prostate cancer: Results of a phase I study : 2010 Genitourinary Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract #193
Chung I, Han G, Seshadri M, Gillard BM, Yu W-D, Foster BA, Trump DL, Johnson CS. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer research 2009; 69(3):967-975
Fakih MG, Trump DL, Johnson CS, Tian L, Muindi J, Sunga AY. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. International journal of colorectal disease 2009; 24(2):219-224
Muindi JR, Johnson CS, Trump DL, Christy R, Engler KL, Fakih MG. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 2009; 65(1):33-40
Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. Journal of urology 2009; 181(2):621-626
Sonpavde G, Grossman HB, Natale RB, Trump DL, Vogelzang NJ, Wood DP, Lerner SP, Speights VO, Goldman BH, Crawford ED. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009; 115(18):4104-4109
Trump DL, Tan W, Tian L, Nesline MK, Hollis BW, Silliman CG, Ashraf U, Fakih MG, Sunga AY, Chadha MK, Johnson CS. Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU international 2009; 104(7):909-914
Yao S, O'Connor TL, Edge SB, Kulkarni S, Hwang H, McCann SE, Hong C-C, Davis W, Nesline MK, Trump DL, Johnson CS, Millen AE, Sucheston LE, Ambrosone CB. Pretreatment serum concentrations of 25-hydroxyvitamin d and breast cancer prognostic characteristics: a case-control and a case-series study. PloS one 2011; 6(2):e17251
Johnson CS, Ma YY, Yu WD, Trump DL. Calcitriol-mediated antitumor effects: role in human bladder cancer. Anticancer research 2011; 31(4):20
Malone EK, Rassnick KM, Wakshlag JJ, Russell DS, Al-Sarraf R, Ruslander DM, Johnson CS, Trump DL. Efficacy of vitamin D (calcitriol) for canine mast cell tumors. Journal of veterinary internal medicine 2011; 25(3):756
Peppone LJ, Purnell JQ, Janelsins MC, Mustian KM, Trump DL, Zakharia Y, Rosier RN, Reid ME, Huston AJ, Morrow GR. The effect of various vitamin D supplementation regimens in breast cancer patients. Breast cancer research and treatment 2011; 127(1):171-177
Trump DL, Al-Hussaini M, Silliman C, Nesline M, Johnson CS. Randomized study of 4,000 IU, 6,000 IU, 8,000 IU or 10,000 IU of cholecalciferol in men with prostate cancer: Toxicity and 25(OH)D(3) effects. Anticancer research 2011; 31(4):1496 (Abstract #16)
Camoriano M, Kinney SR, Moser MT, Foster BA, Mohler JL, Trump DL, Karpf AR, Smiraglia DJ. Phenotype-specific CpG island methylation events in a murine model of prostate cancer. Cancer research 2008; 68(11):4173-4182
Chadha MK, Ashraf U, Lawrence D, Tian L, Levine E, Silliman C, Escott P, Payne V, Trump DL. Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer. Prostate 2008; 68(13):1461-1466
Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S, Resnick NM. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. Journal of clinical oncology 2008; 26(27):4426-4434
Lau YK, Chadha MK, Litwin A, Trump DL. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature. Journal of hematology and oncology 2008; 1:21
Ma Y, Yu WD, Hershberger PA, Flynn G, Kong RX, Trump DL, Johnson CS. 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Molecular cancer therapeutics 2008; 7(9):3047-3055
Rassnick KM, Muindi JR, Johnson CS, Balkman CE, Ramnath N, Yu WD, Engler KL, Page RL, Trump DL. In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. Cancer chemotherapy and pharmacology 2008; 62(5):881-891
Alagbala AA, Moser MT, Johnson CS, Trump DL, Foster BA. Characterization of Vitamin D insensitive prostate cancer cells. Journal of steroid biochemistry and molecular biology 2007; 103(3-5):712-716
Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer chemotherapy and pharmacology 2007; 59(5):581-587
Chung I, Karpf AR, Muindi JR, Conroy JM, Nowak NJ, Johnson CS, Trump DL. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. Journal of biological chemistry 2007; 282(12):8704-8714
Chung I, Yu WD, Karpf AR, Flynn G, Bernardi RJ, Modzelewski RA, Johnson CS, Trump DL. Anti-proliferative effects of calcitriol on endothelial cells derived from two different microenvironments. Journal of steroid biochemistry and molecular biology 2007; 103(3-5):768-770
Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature reviews. Cancer 2007; 7(9):684-700
Fakih MG, French R, Hutson A, Brattain MG, Schwartz J, Creaven PJ, Bernardi RJ, Black JD, Muindi JR, Trump DL, Johnson CS. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clinical cancer research 2007; 13(4):1216-1223
Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Annals of internal medicine 2007; 146(6):416-424
Gupta S, Silliman CG, Trump DL. Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation. Prostate cancer and prostatic diseases 2007; 10(4):396-397
Hidalgo AA, Paredes R, Garcia VM, Flynn G, Johnson CS, Trump DL, Onate SA. Altered VDR-mediated transcriptional activity in prostate cancer stroma. Journal of steroid biochemistry and molecular biology 2007; 103(3-5):731-736
Hussain MH, Smith DC, Chen H, Trump DL, Glode LM, Nanus DM, Chatta GS, Lara PN Jr, Vaishampayan U, Dunn RL, Petrylak DP, MacVicar GR, National Cancer Institute. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. Journal of clinical oncology 2007; 25(16):2218-2224
Muindi JR, Nganga A, Engler KL, Coignet LJ, Johnson CS, Trump DL. CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. Journal of steroid biochemistry and molecular biology 2007; 103(3-5):334-337
Muindi JR, Peng Y, Wilson JW, Johnson CS, Branch RA, Trump DL. Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patients. Cancer chemotherapy and pharmacology 2007; 59(1):97-104
Deeb KK, Johnson CS, Morrison CD, Tangrea MA, Tian L, Bshara W, Omilian AR, Karpf AR, Luo W, Trump DL. Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate. Epigenetics 2011; 6(8):994-1000
Hidalgo AA, Trump D, Johnson C, Pantoja D, Tovar H, McNerney EM, Godoy AS, Paredes R, Montecinos VP, Onate SA. Biochemical characterization of nuclear receptors for vitamin D3 and glucocorticoids in prostate stroma cell microenvironment. Biochemical and biophysical research communications 2011; 412(1):13-19
Scosyrev E, Crawford ED, Tangen CM, Natale RB, Trump DL, Vogelzang NJ, De Vere White RW, Wood DP, Grossman HB, Speights VO, Messing EM, Ely BW, Thompson IM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU international 2011; 108(5):693-699
Trump DL, Morris T, Taboada M, Nathan F, Burris HA 3rd, Stephenson J 3rd, de Bono JS, Miller K, Payne H, Hubner A. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Prostate 2011; 71(12):1264-1275
Woloszynska-Read A, Johnson CS, Trump DL. Vitamin D and cancer: Clinical aspects. Best practice and research. Clinical endocrinology and metabolism 2011; 25(4):605-615
Jain RK, Trump DL, Egorin MJ, Fernandez M, Johnson CS, Ramanathan RK. A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors. Investigational new drugs 2011; 29(6):1420-1425
Mazzilli SA, Reid ME, Foster BA, Trump DL, Johnson CS. The effects of vitamin D on the tumorigenesis of lung squamous cell carcinoma in a carcinogen incduced mouse model. Journal of thoracic oncology 2011; 6(6 Suppl. 2):S939-S940
AL-Hussaini MH, Johnson CS, Muindi J, Chadha MK, Silliman C, Tian L, Tan W, Nesline M, Sandecki A, Kuettel MR, Mohler J, Guru K, Trump DL. Serum 25(OH) vitamin D3 response to vitamin D3 supplementation in men with prostate cancer: Results of a randomized phase II trial : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):e13060
Trump DL, AL-Hussaini MH, Silliman C, Jarkowski A, Johnson CS. Effect of ketoconazole/hydrocortisone (Keto/HC) on 25 (OH) vitamin D in men with castration-resistant prostate cancer (CRPC) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):e13063
Chadha MK, Fakih MG, Tian L, Mashtare T, Nesline M, Davis W, Silliman C, Trump DL. Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e20575
Chung I, Karpf AR, Nowak NJ, Kong R-X, Trump DL, Johnson CS. Tumor-conditioned media induces CYP24 epigenetic silencing and sensitivity to calcitriol in matrigel-derived endothelial cells (MDEC). Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:135
Chung I, Seshadri M, Yu W-D, Khan M, Trump DL, Johnson CS. In vivo function of vitamin D receptor (VDR) in tumor angiogenesis. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:1094
Houde C, Dolce J, Bundy B, Nesline M, Davis W, Ambrosone C, McLaughlin W, Trump D, Coignet L. The presence of the FRA12E/SMRT fragile site in the genome of prostate cancer (CaP) patients is a predictor of metastatic development. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:36
Iyer R, Tennant B, Brekken R, Rivera L, Pendyala L, Wu J, Fetterly G, Johnson C, Trump D. Woodchuck hepatocellular cancer (HCC): a translational model for developing anti-angiogenic therapies for human hepatocellular cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:690
Johnson CS, Trump DL. Differences in epigenetic silencing of calcitriol-induced CYP24 gene expression in endothelial cells from the tumor microenvironment. Anticancer research 2008; 28(3A):1618 (Abstract #12)
Ma Y, Su B, Yu W-D, Kong R-Y, Trump DL, Johnson CS. 1,25D(3) regulates adhesion, migration and invasion of squamous cell carcinoma cells. Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:1088
Ma Y, Yu W-D, Flynn G, Hershberger PA, Kong R-X, Trump DL, Johnson CS. 1,25D3 potentiates the cytotoxic effects of cisplatin through up-regulation of p73 and enhancement of apoptosis in squamous cell carcinoma cells. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:107
Ma Y, Yu W-D, Kong R-X, Trump DL, Johnson CS. 1,25D(3) enhances antitumor effects of cisplatin and gemcitabine in human bladder cancer model systems. Proceedings of the American Association for Cancer Research Annual Meeting 2009; 50:206
Muindi JR, Adjei AA, Panasiewicz MA, Wu ZR, Tian L, Sucheston LE, Johnson CS, Trump DL, Fakih MG. Profiling serum vitamin D-3 metabolites in colorectal cancer patients on cholecalciferol supplementation.: Correlation with single nucleotide polymorphisms (SNPs) in the major vitamin D-3 metabolizing genes. Proceedings of the American Association for Cancer Research Annual Meeting 2009; 50:827
Nganga A, Engler KL, Johnson CS, Trump DL, Coignet LJ, Muindi JR. CYP24A1 polymorphisms and splicing variants associated with different patterns of vitamin D metabolism in human cancer cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:175
Pahk A, McCarthy P, Smiley S, Nava H, Yang G, Smith J, Trump D, Battiwalla M, Andrews C, Schiff M. Wireless Capsule Endoscopy as a Diagnostic Tool and Predictor of Acute and Chronic Graft-Versus-Host Disease. American journal of gastroenterology 2009; 104(Suppl. 3):Abstract #1354
Sunga AY, Levea C, Fakih M, Reid M, Mahoney M, Smith J, Trump D, Johnson C, Schiff M. Aberrant crypt foci characterization in selected colorectal cancer risk groups. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:397
Trump DL, Fakih M, Chung I, Johnson CS. Vitamin D: Sunshine, diet and supplements-cancer prevention and therapy. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:1366-1367
Trump DL, Johnson CS. Clinical development of high dose vitamin D in cancer: Current status. Anticancer research 2008; 28(3A):1625 (Abstract #30)
Yu W-D, Ma Y, Engler K, Kong R-X, Muindi J, Trump DL, Johnson CS. 19-Nor-1,25(OH)2D2 in conjunction with gemcitabine induces antiproliferative activity through the suppression of 24-hydroxylase activity and the enhancement of apoptosis in a human pancreatic carcinoma cell line. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:456
Yu W-D, Ma Y, Kong R-X, Trump DL, Johnson CS. Calcitriol and taxotere suppress bone metastases in PC-3M-luc-C6 prostate cancer mouse model as monitored by bioluminescence imaging. Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:872
Hidalgo AA, Deeb KK, Pike JW, Johnson CS, Trump DL. Dexamethasone enhances 1alpha,25-dihydroxyvitamin D3 effects by increasing vitamin D receptor transcription. Journal of biological chemistry 2011; 286(42):36228-36237
Trump DL, Al-Hussaini M, Silliman C, Nesline M, Johnson CS. Randomized study of 4,000 IU, 6,000 IU, 8,000 IU or 10,000 IU of cholecalciferol in men with prostate cancer: Toxicity and 25(OH)D(3) effects. Anticancer research 2011; 31(4):1496
Wakshlag JJ, Rassnick KM, Malone EK, Struble AM, Vachhani P, Trump DL, Tian LL. Cross-sectional study to investigate the association between vitamin D status and cutaneous mast cell tumours in Labrador retrievers. British journal of nutrition 2011; 106(Suppl. 1):S60-S63
Luo W, Karpf AR, Chernov M, Johnson C, Trump D. Protein kinase CK2 contributes to 1, 25-dihydroxyvitamin D3-mediated CYP24A1 gene expression in prostate cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #942
Ma Y, Yu W-D, Kong R-X, Delansorne R, Trump DL, Johnson CS. Inecalcitol, a 14-epi-analogue of 1,25D3, induces growth inhibition through apoptosis and cell cycle arrest in a squamous cell carcinoma model system. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #583
Krishnan AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. Rheumatic diseases clinics of North America 2012; 38(1):161-178
Yao S, Zirpoli G, Bovbjerg DH, Jandorf L, Hong CC, Zhao H, Sucheston LE, Tang L, Roberts M, Ciupak G, Davis W, Hwang H, Johnson CS, Trump DL, McCann SE, Ademuyiwa F, Pawlish KS, Bandera EV, Ambrosone CB. Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study. Breast cancer research : BCR 2012; 14(2):R58
Ramnath N, Daignault-Newton S, Dy GK, Muindi J, Adjei A, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Johnson CS, Trump DL. A phase I/II clinical trial of intravenous (I.V.) calcitriol with fixed doses of cisplatin and docetaxel in advanced non-small cell lung cancer. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e18118
Kotowski AS, Stegemann A, Rehman S, Attwood K, Levine EG, Guru K, Trump DL, Pili R. A single-center experience of chemotherapy for muscle-invasive bladder cancer after radical cystectomy : 2012 Genitourinary Cancers Symposium. Journal of clinical oncology 2012; 30(5 Suppl.):Abstract #318

Referral

Email:

Donald.Trump@RoswellPark.org

Fax:

716-845-8261